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Abstract
Kappa opioid receptor (KOR) modulation is a promising target for drug discovery efforts due to 
KOR involvement in pain, depression, and addiction behaviors. We recently reported a new class 
of triazole KOR agonists that displays significant bias toward G protein signaling over βarrestin2 
recruitment; interestingly, these compounds also induce less activation of ERK1/2 map kinases 
than the balanced agonist, U69,593. We have identified structure–activity relationships around the 
triazole scaffold that allows for decreasing the bias for G protein signaling over ERK1/2 activation 
while maintaining the bias for G protein signaling over βarrestin2 recruitment. The development of 
novel compounds, with different downstream signaling outcomes, independent of G protein/
βarrestin2 bias, provides a more diverse pharmacological toolset for use in defining complex KOR 
signaling and elucidating the significance of KOR-mediated signaling.
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Kappa opioid receptor (KOR) signaling is involved in numerous biological processes. KOR 
agonists produce antinociception without the physical dependence and respiratory failure 
associated with mu opioid receptor-directed pain therapies.1–4 Additionally, KOR plays a 
role in dopaminergic and serotonergic pathways in the CNS wherein KOR activation can 
decrease dopamine levels. When concomitantly administered with drugs of abuse, such as 
cocaine, KOR agonists can decrease the reinforcing and rewarding effects.5–9 When 
administered prior to a stress-inducing event, KOR antagonists can prevent the decrease in 
dopamine that triggers relapse in drug extinction paradigms.10,11 KOR antagonists have 
been shown to have antidepressant and anxiolytic effects.12–14 These observed behavioral 
effects suggest KOR modulation is a promising therapeutic target for the treatment of pain, 
drug addiction, and depression. Additionally, a partial KOR agonist is currently used 
clinically in the treatment of intractable itch.15–18 However, aversive side effects such as 
dysphoria, sedation, dissociation, diuresis, and depression all limit the therapeutic potential 
of KOR agonism.2,3,10,19–22
Currently it is hypothesized that the antinociception associated with KOR agonism results 
from G protein mediated signaling events while certain negative side effects may result from 
βarrestin2-mediated signaling events.23 Thus, developing KOR agonists that are biased 
toward G protein coupling and away from βarrestin2 recruitment will serve as important 
tools for delineating the contributions of each pathway to the physiological effects of KOR 
activation.24–28 Recently, we reported on a number of selective KOR agonists of a triazole 
scaffold that display functional selectivity, or “bias”, toward G protein signaling over 
βarrestin2 recruitment.29,30
In addition to looking at G protein signaling and βarrestin2 recruitment, ERK1/2 signaling 
was investigated as ERK activation can occur via G protein-dependent or βarrestin2-
dependent signaling pathways.31–35 In the initial series of five triazoles, we noted that, in 
each case, the profiles for activating ERK1/2 paralleled their profiles for activating 
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βarrestin2 recruitment to KOR. In other words, all of the previously reported triazoles have 
low potency for activating ERK1/2 although they maintain potency and efficacy in 
mediating G protein signaling.29 This is very different from 6′GNTI, a previously described 
G protein/βarrestin2 biased agonist, as 6′GNTI promotes potent ERK1/2 activation in the 
cell lines that parallels its ability to activate G protein signaling. These observations 
demonstrate that while two agonists may display bias for G protein signaling over βarrestin2 
recruitment, the observed bias is not necessarily predictive of how the agonist will induce 
downstream signaling to MAP kinases. Herein we evaluate the triazole structure–activity 
relationship and show that the bias for ERK activation can be altered while preserving 
βarrestin2 bias with respect to G protein signaling.
RESULTS AND DISCUSSION
The compounds examined in this study were selected based on trends observed in initial 
screening of compounds developed in iterative rounds of chemistry around the triazole 
scaffold initially described by Zhou et al. (Figure 1).29 In these three examples, we 
investigate the contribution of the three substitutions, namely, the furan, thiophene, or 
pyridine groups, for their impact on proximal G protein signaling and βarrestin2 recruitment 
as well as upon the downstream activation of ERK1/2. In all studies, test compounds are 
assayed in parallel with the KOR agonist, U69,593, which serves as the reference agonist in 
each of the assays.
G protein signaling studies were performed in membranes from CHO-K1 cells stably 
expressing human KOR (CHO-hKOR) as previously described25,29 (Figure 2A, Table 1). All 
of the triazole compounds display similar potencies to U69,593 ranging from 27 to 149 nM 
and act as full agonists. In each series, the furan and thiophene analogues (X.1 and X.2, 
respectively) have similar potencies while the pyridine analogue (X.3) results in a slight but 
statistically significant decrease in potency relative to either furanyl or thiophenyl 
substitution.
To investigate whether these compounds are biased against βarrestin2 recruitment, they were 
evaluated for their ability to stimulate βarrestin2 recruitment using automated high content 
imaging in U2OS cells stably expressing human KOR and GFP-tagged βarrestin2 (U2OS-
hKOR-βarr2-GFP) as previously described.29 All of the test compounds are weakly potent 
(>2 μM EC50) in the βarrestin2 recruitment assay, a log order difference in potency 
compared to the reference compound, U69,593 (194.2 ± 15.6 nM) (Figure 2B, Table 1). 
Interestingly, the response does not reach a plateau at the highest concentrations tested for 
the triazoles, which was also the case for those initially described.29 Since nonlinear 
regression analysis cannot stringently predict a maximal effect when a plateau is not 
reached, relative efficacy values are also presented as a percent of 10 μM U69,593 
stimulation at 10 μM to facilitate comparisons (Table 1).
ERK1/2 activation was assessed using a multiwell plate immunocytochemistry approach 
with the CHO-hKOR cell line as previously described.25,29 While none of the analogues are 
as potent as U69,593 (7.2 ± 0.9 nM) (Figure 2C, Table 1), an interesting structure–activity 
relationship begins to emerge within each group of the triazole compounds. Specifically, the 
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analogues demonstrate a rank order of potency with substitutions on 4-N of the triazole ring: 
thiophenyl (X.2) < furanyl (X.1) < pyridinyl (X.3). As with the previously reported 
triazoles,29 each new triazole analogue tends to produce a greater maximal stimulation of 
ERK1/2 compared to U69,593.
In order to compare the activity of these agonists across multiple signaling platforms, it is 
necessary to address the system-dependent properties of each response. These can include 
differences in receptor number and response amplification as well as other properties that are 
specific to each system. Therefore, we present several different forms of analysis to provide 
evidence that the SAR trend we observe is the result of a change in the system independent 
effects of the ligands. In one effort to contrast the changes in ERK phosphorylation by the 
pyridine analogues (X.3) with the effect of these analogues in βarresin2 recruitment, the 
percent maximum stimulation at each concentration for [35S]GTPγS binding (abscissa) was 
graphed versus the percent maximum stimulation at each concentration for βarrestin2 
recruitment (ordinate, left) and ERK 1/2 phosphorylation (ordinate, right) (Figure 3). This 
equimolar graph was originally proposed by Gregory et al.36 In this representation, a 
compound that produces an equivalently efficacious response in each assay at each dose 
tested, a linear correlation would be derived (shown in the pink curve for reference). One 
can readily see that the modifications at the 4-N position of the triazole ring has little effect 
on modulating βarrestin2 recruitment relative to G protein signaling (all the curves overlap 
and are rightward of U69,593). When ERK and G protein signaling are compared, the 
pyridinyl group substitution (X.3) leads to an ERK activation profile that becomes closer to 
that obtained with U69,593.
In a second effort to quantitatively assess and compare the potencies in each signaling assay, 
the relative activity of each test agonist was estimated using the method described by Griffin 
et al.37 This method incorporates both the potency and maximum response of each test 
agonist to produce a single value of relative activity that can be compared between responses 
relative to the performance of a full agonist, the reference agonist (here U69,593) in each 
system; Figure 4A presents the comparison of the relative activity of each test agonist. While 
this manner of analysis helps to visualize the empirical relationship of the responses 
produced by each test agonist, the analysis does not consider inherent differences between 
the assay systems that are compared.38 Therefore, to gain a more quantitative comparison 
between compounds, the data in Figure 2 were fit to the operational model to produce 
estimates of the relative intrinsic activity of each test agonist in each measure of response 
(Table 2).29,38,39 The derived values, comparing G protein coupling versus βarrestin2 
recruitment or ERK1/2 activation, are plotted as “bias factors” in Figure 4B and as ΔΔLogR 
values including standard error of the mean calculations in Table 2.
For both the G protein coupling and βarrestin2 recruitment data, the fit of the model 
provided straightforward parameter estimates for each agonist (ΔLogR; Table 2). When 
considering the preference for G protein signaling over βarrestin2 recruitment 
(ΔΔLogRG−βarr2), substitutions at the 4-N position on the triazole ring have no conserved 
effect of either increasing or decreasing the degree of bias seen when comparing compound 
performance in these assays. However, comparison of the X.1, X.2, and X.3 substitutions at 
this position produce a conserved change in bias factors when comparing G protein 
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signaling and ERK1/2 activation (ΔΔLogRG−ERK, Figure 4B, Table 2). For each scaffold, the 
thiophene (X.2) substitution produces a greater bias factor for G protein signaling over 
ERK1/2 activation while the pyridine (X.3) substitution produces a smaller bias factor when 
compared to the furan (X.1) substitution. In Table 2, standard error of the mean values and 
95% confidence intervals are presented to suggest that these differences may prove to be 
statistically significant; however, the rigor of statistics for propagating error of comparison 
over multiple populations has not been applied.
The results of all of these forms of analysis lead us to conclude that the incorporation of a 
basic nitrogen atom in one of the heterocycles attached to the triazole does not lead to a 
universal trend for altering bias toward G protein coupling compared to βarrestin2 
recruitment. However, a conserved trend becomes apparent when comparing G protein bias 
over activating ERK1/2. To facilitate further comparisons, the ratio of bias factors obtained 
for each comparison were calculated from 10^(ΔΔLogRG−βarr2)/10^(ΔΔLogRG−ERK); the 
bias factor ratios are plotted as a summary schematic in Figure 5. Importantly, these findings 
demonstrate that biasing G protein signaling versus βarrestin2 recruitment or ERK 1/2 
phosphorylation has the potential to be independent of one another.
In summary, through structural modification of the 4-N substituent of the triazole scaffold 
we were able identify three series of compounds with conserved substitutions that have little 
effects on altering the bias between G protein signaling and βarrestin2 recruitment, but 
produce pronounced and conserved variations in bias between G protein signaling and 
ERK1/2 activation. If only considered for the G protein bias over βarrestin2 recruitment 
profiles, little difference would be evident among the nine compounds. By revealing the 
differences in the degrees of bias against ERK1/2 activation, these compounds will serve as 
important probes for evaluating how the different aspects of biased signaling will be 
reflected in other pharmacological as well as physiological effects at KOR. What remains is 
the question of how these compounds, which clearly differ in the cell-based assays, will 
perform in the endogenous setting. Since bias is highly context dependent (the receptor can 
only interact with intracellular components that are expressed where the receptor is 
expressed for example), further studies with these compounds will be necessary in an 
endogenous setting. Therefore, these studies inform only as to the differences between how 
the compounds can perform under the conditions analyzed and in comparison to the 
performance of a reference agonist, U69,593. Studies in endogenous tissues and in vivo will 
help to understand how bias profiles in cell based assays can be predictive (or not) of 
signaling induced at the multiple and diverse expression locations of the KOR in vivo.
METHODS
Compounds and Reagents for Biological Studies
Control (+)-(5α,7α,8β)-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-
benzeneacetamide (U69,593) was purchased from Sigma-Aldrich. U69,593 was prepared in 
ethanol as a 10 mM stock, and test compounds were prepared as 10 mM stocks in DMSO 
(Fisher). All compounds were then diluted further in DMSO and then to working 
concentrations in vehicle for each assay without exceeding 1% DMSO or ethanol 
concentrations. [35S]GTPγS was purchased from PerkinElmer Life Sciences (Waltham, 
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MA). Phospho-ERK1/2 and total ERK1/2 antibodies were purchased from Cell Signaling 
(Beverly, MA) and Li-Cor secondary antibodies (antirabbit IRDye800CW and antimouse 
IRDye680LT) were purchased from Li-Cor Biosciences (Lincoln, NE).
Cell Lines and Cell Culture
Previously described Chinese hamster ovary (CHO) cells virally transfected to express HA-
tagged recombinant human kappa opioid receptors (CHO-hKOR) were maintained in 
DMEM/F-12 media (Invitrogen) supplemented with 10% fetal bovine serum, 1% penicillin/
streptomycin, and 500 μg/mL Geneticin.25,29 A stable U2OS cell line expressing hKOR and 
βarrrestin2-eGFP (U2OS-hKOR-βarrestin2-GFP) was a gift from Dr. Lawrence Barak, Duke 
University. These cells were maintained in minimum Eagle’s medium with 10% fetal bovine 
serum, 1% penicillin/streptomycin, 500 μg/mL Geneticin, and 50 μg/mL zeocin. All cells 
were grown at 37 °C (5% CO2 and 95% relative humidity).
[35S]GTPγS Coupling
[35S]GTPγS Coupling was performed following a previously published protocol.25,29 
Briefly, cells were serum-starved for 1 h, collected in 5 mM EDTA, and stored at −80 °C 
until needed. Membranes were prepared in membrane preparation buffer (10 mM Tris-HCl, 
pH 7.4, 100 mM NaCl, 1 mM EDTA). Each reaction was performed at room temperature for 
1 h and contained 15 μg of membrane protein, ~0.1 nM [35S]GTPγS, and increasing 
concentrations of test compound to yield a total volume of 200 μL in assay buffer (50 mM 
Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM MgCl2, 1 mM EDTA, and 3 μM GDP). Reactions 
were quenched using a 96-well plate harvester (Brandel Inc., Gaithersburg, MD) and filtered 
through GF/B filters (PerkinElmer Life Sciences). Filters were dried and imaged with a 
TopCount NXT high throughput screening microplate scintillation and luminescence counter 
(PerkinElmer Life Sciences).
βArrestin2 Imaging
βArrestin2 imaging was performed following a previously published protocol.29 In short, 
U2OS-hKOR-βarr2-GFP cells were plated at a cell density of 5000 cells per well and 
incubated at 37 °C overnight. After a 30 min serum starve, cells were treated with increasing 
drug concentration for 20 min at 37 °C and fixed with prewarmed 4% paraformaldehyde and 
stained with Hoechst stain (1:000) for 30 min. Images were acquired with a ×20 objective on 
the CellInsight High Content Screening Platform (Thermo Scientific) and the number of 
spots per cell was determined using the Cellomics Spot Detector BioApplication algorithm 
(version 6.0).
In-Cell Western ERK1/2 Phosphorylation
Assay was performed following previously published protocols.25,29 Briefly, hKOR-CHO 
cells were plated in 384-well plate at 15 000 cells per well and incubated at 37 °C overnight. 
After a 1 h serum starve and 10 min drug treatment, cells were fixed, permeabilized, 
blocked, and stained with primary antibodies for phosphorylated ERK1/2 and total-ERK1/2 
(1:300 and 1:400, respectively) at 4 °C overnight. Cells were imaged with Li-Cor secondary 
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antibodies (antirabbit IRDye800CW, 1:500; anti-mouse IRDye680LT, 1:1500) using an 
Odyssey Infrared Imager (Li-Cor Biosciences, Lincoln, NE) at 700 and 800 nm.
Data Analysis and Statistics
Concentration response curves were generated using three-parameter nonlinear regression 
analysis on GraphPad Prism 6.01 software (GraphPad, La Jolla, CA). In each experiment, 
compound concentrations were run in parallel between 2 and 4 replicates in each individual 
experiment and n ≥ 3 for independent experiments was performed. In each individual 
experiment, compounds were normalized to the maximal U69,593 stimulation and the 
nonlinear regression analysis performed on each individual curve were averaged to yield 
efficacy and potency values reported as the mean ± SEM.
In order to determine the bias of the test ligands, each data set was fit to the operational 
model.37,38 This form of bias analysis employs a reference ligand that is assumed to be a full 
neutral agonist (i.e., the reference agonist activates all response pathways equally and does 
not exhibit a preference for one pathway over another). In the experiments presented here, 
U69,593 was used as the reference agonist and the U69,593 concentration curves were fit to 
the equation, from Griffin et al.,37 in each set of experiments:
(1)
In this equation, top represents the maximum response of the system, bottom represents the 
basal level of stimulation in the system, n represents the transducer slope, LogX represents 
the log of the concentration of U69,593 used (expressed in molar units), and LogKreference 
represents the log of the affinity constant of U69,593. When this equation is applied to the 
concentration–response curve, a value for the LogRreference parameter is produced. 
LogRreference is a single composite parameter that represents the product of the intrinsic 
agonist activity of the reference agonist (otherwise known as the τreference of the reference 
compound) and the affinity constant of the reference agonist (LogKreference).
By combining τreference and LogKreference into a single parameter in the equation, it is 
possible to achieve a highly accurate estimate of the LogRreference. It is not possible to 
directly estimate either τreference or LogKreference individually. Similarly, each test compound 
was fit to the equation, from Griffin et al., in each set of experiments:
(2)
This equation shares many parameter definitions with eq 1. Specifically, top, bottom, n, and 
LogR are all identical to the parameters defined for eq 1. Similarly, LogKtest represents the 
log of the affinity constant of the test agonist and LogX represents the log of the 
concentration of the test agonist used (in molar units). When the test agonist is fit with eq 2 
and the reference agonist is simultaneously fit with eq 1, the value of LogRreference is held 
constant for the two equations. The parameter ΔLogR is defined as the difference between 
the LogRtest of the test agonist and the LogRreference (ΔLogR = LogRTest − LogRreference). 
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Since the LogRreference is held constant between the two equations, the ΔLogR of each test 
agonist can be directly determined in each experiment. In order to determine the bias of a 
test ligand for different signaling cascades, the ΔLogR of each test agonist in multiple 
experiments was averaged and the difference in this averaged ΔLogR for each test agonist, in 
each response was calculated as
(3)
This difference in the ΔLogR of the test agonist for the two measures of response, defined as 
ΔΔLogR, provides a measure of the bias of the test agonist between the two responses. 
Specifically, the bias factor of each test agonist is defined as the antilog of the ΔΔLogR.38 
The 95% confidence interval of the test agonists’ ΔΔLogR values (Table 2) support the 
preliminary finding that each test agonist is biased for G protein coupling over the other 
pathways under investigation.
Several parameters were constrained in this analysis in order to achieve accurate measures of 
each test agonist’s ΔLogR. As stated above, the LogRreference of the reference agonist was 
held constant when applied to both the test agonist and the reference agonist. Additionally 
the parameter n, the transducer slope, was also constrained to be shared for all agonists in 
each experiment. Similarly, the Bottom and Top parameters were shared for all agonists 
because the basal and maximal response of the system can be assumed to be the same for all 
agoinsts. The affinity constant of the test agonist, LogKtest, was constrained to the range of 
1fM to 1 M, and the ΔLogR was constrained so that the absolute value of the ΔLogR of the 
test agonist was less than 10. The constraints were applied to the LogKtest and ΔLogR we 
chose in order to allow the fitted values for these parameters to be interpreted as meaningful 
and useful.
Compounds and Reagents for Chemical Synthesis
Except as noted below, reagents and materials were purchased from commercial vendors 
(Sigma, Alfa Aesar, TCI America, Fisher Scientific) and used as received. Ethyl ether, 
toluene, THF, MeCN, and CH2Cl2 were degassed with nitrogen and passed through two 
columns of basic alumina on an Innovative Technology solvent purification system. 1H 
and 13C NMR spectra were recorded on a Bruker AM 400 spectrometer (operating at 400 
and 100 MHz respectively) in CDCl3 with 0.03% TMS as an internal standard, unless 
otherwise specified. Chemical shifts are reported in parts per million (ppm) downfield from 
TMS. 13C Multiplicities were determined with the aid of an APT pulse sequence, 
differentiating the signals for methyl and methine carbons as “d” from methylene and 
quaternary carbons as “u”. The infrared (IR) spectra were acquired as thin films using a 
universal ATR sampling accessory on a PerkinElmer Spectrum 100 FT-IR spectrometer and 
the absorption frequencies are reported in cm−1. Melting points were determined on a 
Stanford Research Systems Optimelt automated melting point system interfaced through a 
PC and are uncorrected.
HPLC/MS analysis was carried out with gradient elution (5% CH3CN to 100% CH3CN) on 
an Agilent 1200 HPLC with a photodiode array UV detector and an Agilent 6224 TOF mass 
spectrometer (also used to produce high resolution mass spectra). One of two column/mobile 
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phase conditions were chosen to promote the target’s neutral state (0.02% formic acid with 
Waters Atlantis T3 5um, 19 × 150 mm; or pH 9.8 NH4OH with Waters XBridge C18 5 um, 
19 × 150 mm).
The furan- and thiophene-containing thione substrates were synthesized as previously 
described.30 The synthesis of the 3-pyridine-containing thione substrate as well as HPLC 
chromatograms and images of the NMR spectra are provided in the Supporting Information.
General Procedure for the Synthesis of Triazole Analogues
The previously reported protocol was utilized for the synthesis of novel triazole analogues.30 
Thus, the thione scaffold (0.1–0.3 mmol), K2CO3 (2 equiv), and the benzyl halide (1.2 
equiv) were combined in acetone (15 mL/mmol substrate) and stirred at rt in a sealed vial. 
After 15 h, the solvent was removed and the residue washed with CH2Cl2 (2 × 3 mL) and 
filtered. The combined filtrates were evaporated and purified by silica gel chromatography to 
afford the triazole thioether product.
1.1. 2-(5-((2-Chloro-5-(trifluoromethyl)benzyl)thio)-4-(furan-2-yl-
methyl)-4H-1,2,4-triazol-3-yl)pyridine—The furan-containing thione (52 mg, 0.20 
mmol) and 2-chloro-5-(trifluoromethyl)benzyl bromide (66 mg, 0.24 mmol, 1.2 equiv) were 
reacted according to the general procedure to afford the product as a white solid (74 mg, 
0.17 mmol, 83% yield). Mp = 109–114 °C; Rf = 0.51 (1:1 hexanes/EtOAc). 1H NMR 
(CDCl3) δ 4.65 (s, 2H), 5.81 (s, 2H), 6.12 (d, J = 2.8 Hz, 1H), 6.19 (dd, J = 2.0, 3.2 Hz, 1H), 
7.23 (d, J = 1.2 Hz, 1H), 7.34 (ddd, J = 1.2, 4.8, 7.6 Hz, 1H), 7.46–7.52 (m, 2H), 7.74 (d, J = 
0.8 Hz, 1H), 7.81 (dt, J = 1.6, 8.0 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.64 (d, J = 4.8 Hz, 
1H). 13C NMR (CDCl3, APT pulse sequence) δ d 109.0, 110.4, 123.4, 124.1, 125.9 (q, J = 
3.6 Hz), 128.1 (q, J = 3.7 Hz), 130.2, 137.0, 142.7, 148.5; u 35.4, 41.9, 123.4 (d, J = 273.3 
Hz), 129.5 (q, J = 33.2 Hz), 135.8, 138.1, 147.7, 148.9, 152.1, 152.8. IR (neat) 1590, 1463, 
1446, 1423 cm−1. HRMS (ESI) m/z calcd for C20H15ClF3N4OS ([M + H]+), 451.0607; 
found, 451.0619. HPLC purity = 99.6%.
1.2. 2-(5-((2-Chloro-5-(trifluoromethyl)benzyl)thio)-4-(thiophen-2-
ylmethyl)-4H-1,2,4-triazol-3-yl)pyridine—The thiophene-containing thione (55 mg, 
0.20 mmol) and 2-chloro-5-(trifluoromethyl)benzyl bromide (66 mg, 0.24 mmol, 1.2 equiv) 
were reacted according to the general procedure to afford the product as a white solid (90 
mg, 0.19 mmol, 96% yield). Mp = 118–121 °C; Rf = 0.58 (1:1 hexanes/EtOAc). 1H NMR 
(CDCl3) δ 4.65 (s, 2H), 5.90 (s, 2H), 6.84 (dd, J = 3.6, 5.2 Hz, 1H), 7.00 (dd, J = 1.2, 3.2 Hz, 
1H), 7.14 (dd, J = 1.2, 5.2 Hz, 1H), 7.35 (ddd, J = 1.2, 4.8, 7.6 Hz, 1H), 7.44–7.51 (m, 2H), 
7.73 (d, J = 2.0 Hz, 1H), 7.82 (dt, J = 1.6, 8.0 Hz, 1H), 8.30 (td, J = 1.2, 8.0 Hz, 1H), 8.66 
(ddd, J = 0.8, 2.0, 4.8 Hz, 1H). 13C NMR (CDCl3, APT pulse sequence) δ d 123.3, 124.2, 
126.0 (q, J = 3.7 Hz), 126.4, 126.5, 127.7, 128.1 (q, J = 3.7 Hz), 130.2, 137.1, 148.5; u 35.4, 
43.7, 123.4 (d, J = 273.5 Hz), 129.3 (q, J = 33.1 Hz), 135.8, 137.7, 138.1, 147.6, 151.8, 
152.6; IR (neat) 1590, 1463, 1445, 1417 cm−1. HRMS (ESI) m/z calcd for C20H15ClF3N4S2 
([M + H]+), 467.0379; found, 467.0375. HPLC purity = 100%.
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ylmethyl)-4H-1,2,4-triazol-3-yl)pyridine—The 3-pyridine-containing thione (50 mg, 
0.19 mmol) and 2-chloro-5-(trifluoromethyl)benzyl bromide (61 mg, 0.22 mmol, 1.2 equiv) 
were reacted according to the general procedure to afford the product as an off-white solid 
(64 mg, 0.14 mmol, 75% yield). Mp = 122–123 °C; Rf = 0.54 (EtOAc). 1H NMR (CDCl3) δ 
4.65 (s, 2H), 5.76 (s, 2H), 7.14 (ddd, J = 0.8, 4.8, 7.6 Hz, 1H), 7.32 (ddd, J = 1.2, 4.8, 7.6 
Hz, 1H), 7.40 (td, J = 2.0, 7.6 Hz, 1H), 7.46–7.51 (m, 2H), 7.74 (d, J = 1.6 Hz, 1H), 7.82 (dt, 
J = 2.0, 7.6 Hz, 1H), 8.32 (td, J = 1.2, 8.0 Hz, 1H), 8.47 (dd, J = 1.6, 4.8 Hz, 1H), 8.52 (d, J 
= 1.6 Hz, 1H), 8.56 (qd, J = 0.8, 5.2 Hz, 1H). 13C NMR (CDCl3, APT pulse sequence) δ d 
123.4, 123.5, 124.4, 126.1 (q, J = 3.6 Hz), 128.2 (q, J = 3.7 Hz), 130.3, 135.0, 137.3, 148.7, 
149.3, 149.4; u 35.3, 46.5, 123.5 (d, J = 273.4 Hz), 129.6 (q, J = 33.3 Hz), 131.5, 135.7, 
138.1, 147.5, 152.3, 153.0. IR (neat) 1590, 1465, 1446, 1420, 1328 cm−1. HRMS (ESI) m/z 
calcd for C21H16ClF3N5S ([M + H]+), 462.0767; found, 462.0789. HPLC purity = 98.2%.
2.1. 2-(5-((4-Iodobenzyl)thio)-4-(furan-2-ylmethyl)-4H-1,2,4-triazol-3-yl)pyridine
—The furan-containing thione (52 mg, 0.20 mmol) and 4-iodobenzyl bromide (71 mg, 0.24 
mmol, 1.2 equiv) were reacted according to the general procedure to afford the product as a 
tan solid (25 mg, 0.05 mmol, 27% yield). Mp = 123–126 °C; Rf = 0.31 (1:1 hexanes/
EtOAc). 1H NMR (CDCl3) δ 4.43 (s, 2H), 5.82 (s, 2H), 6.11 (dd, J = 0.4, 3.2 Hz, 1H), 6.21 
(dd, J = 1.6, 3.2 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 7.24 (dd, J = 0.8, 2.0 Hz, 1H), 7.34 (ddd, 
J = 1.2, 4.8, 7.6 Hz, 1H), 7.62 (td, J = 1.6, 8.0 Hz, 2H), 7.81 (dt, J = 1.6, 8.0 Hz, 1H), 8.28 
(d, J = 8.0 Hz, 1H), 8.65 (ddd, J = 0.8, 1.6, 4.8 Hz, 1H). 13C NMR (CDCl3, APT pulse 
sequence) δ d 109.0, 110.5, 123.4, 124.2, 131.1, 137.0, 137.8, 142.7, 148.6; u 37.5, 42.0, 
93.4, 136.6, 147.8, 149.0, 152.6, 152.7; IR (neat) 1589, 1483, 1462, 1445, 1421 cm−1. 
HRMS (ESI) m/z calcd for C19H16IN4OS ([M + H]+), 475.0089; found, 475.0098. HPLC 
purity = 98.3%.
2.2. 2-(5-((4-Iodobenzyl)thio)-4-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-
yl)pyridine—The thiopehene-containing thione2 (55 mg, 0.20 mmol) and 4-iodobenzyl 
bromide (71 mg, 0.24 mmol, 1.2 equiv) were reacted according to the general procedure to 
afford the product as a white solid (93 mg, 0.19 mmol, 95% yield). Mp = 125–128 °C; Rf = 
0.34 (1:1 hexanes/EtOAc). 1H NMR (CDCl3) δ 4.42 (s, 2H), 5.91 (s, 2H), 6.85 (dd, J = 3.6, 
5.2 Hz, 1H), 6.96 (dd, J = 1.2, 3.6 Hz, 1H), 7.12–7.16 (m, 3H), 7.34 (ddd, J = 0.8, 5.2, 7.6 
Hz, 1H), 7.61 (td, J = 2.0, 8.4 Hz, 2H), 7.81 (dt, J = 1.6, 8.0 Hz, 1H), 8.30 (d, J = 8.0 Hz, 
1H), 8.67 (d, J = 8.4 Hz, 1H). 13C NMR (CDCl3, APT pulse sequence) δ d 123.3, 124.3, 
126.4, 126.6, 127.7, 131.2, 137.2, 137.8, 148.6; u 37.5, 43.8, 93.5, 136.6, 137.9, 147.8, 
152.4, 152.5. IR (neat) 1588, 1568, 1482, 1462, 1445, 1417 cm−1. HRMS (ESI) m/z calcd 
for C19H16IN4S2 ([M + H]+), 490.9861; found, 490.9866. HPLC purity = 97.9%.
2.3. 2-(5-((4-Iodobenzyl)thio)-4-(pyridin-3-ylmethyl)-4H-1,2,4-tri-azol-3-
yl)pyridine—The 3-pyridine-containing thione (49 mg, 0.18 mmol) and 4-iodobenzyl 
bromide (65 mg, 0.22 mmol, 1.2 equiv) were reacted according to the general procedure to 
afford the product as a colorless oil (72 mg, 0.15 mmol, 82% yield); Rf = 0.34 (EtOAc). 1H 
NMR (CDCl3) δ 4.42 (s, 2H), 5.77 (s, 2H), 7.10 (d, J = 8.8 Hz, 2H), 7.13 (dd, J = 4.8, 7.6 
Hz, 1H), 7.29–7.33 (m, 2H), 7.59 (td, J = 2.0, 8.4 Hz, 2H), 7.81 (dt, J = 2.0, 8.0 Hz, 1H), 
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8.31 (td, J = 0.8, 8.0 Hz, 1H), 8.48 (d, J = 4.0 Hz, 1H), 8.52 (s, 1H), 8.56 (qd, J = 0.8, 4.8 
Hz, 1H). 13C NMR (CDCl3, APT pulse sequence) δ d 123.4, 123.6, 124.4, 131.1, 135.0, 
137.3, 137.9, 148.8, 149.2, 149.3; u 37.3, 46.5, 93.6, 131.7, 136.4, 147.5, 152.7, 152.9; IR 
(neat) 1588, 1482, 1464, 1446, 1419 cm−1; HRMS (ESI) m/z calcd for C20H17IN5S ([M + 
H]+), 486.0249; found, 486.0257. HPLC purity = 98.4%.
3.1. 2-(5-((4-Bromobenzyl)thio)-4-(furan-2-ylmethyl)-4H-1,2,4-tri-azol-3-
yl)pyridine—The furan-containing thione (63 mg, 0.24 mmol) and 4-bromobenzyl bromide 
(73 mg, 0.29 mmol, 1.2 equiv) were reacted according to the general procedure to afford the 
product as a pale yellow solid (59 mg, 0.14 mmol, 57% yield). Mp = 111–115 °C; Rf = 0.31 
(1:1 hexanes/EtOAc). 1H NMR (CDCl3) δ 4.43 (s, 2H), 5.81 (s, 2H), 6.10 (dd, J = 0.8, 3.2 
Hz, 1H), 6.20 (dd, J = 1.6, 3.2 Hz, 1H), 7.23 (dd, J = 0.8, 2.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 
2H), 7.33 (ddd, J = 1.2, 5.2, 7.6 Hz, 1H), 7.41 (td, J = 2.0, 8.4 Hz, 2H), 7.80 (dt, J = 1.6, 8.0 
Hz, 1H), 8.26 (td, J = 0.8, 8.0 Hz, 1H), 8.63 (ddd, J = 0.8, 1.6, 4.8 Hz, 1H). 13C NMR 
(CDCl3, APT pulse sequence) δ d 109.1, 110.5, 123.5, 124.2, 130.9, 131.9, 137.1, 142.7, 
148.7; u 37.5, 42.0, 121.9, 136.0, 147.8, 149.1, 152.7, 152.8. IR (neat) 1589, 1486, 1462, 
1445, 1421 cm−1. HRMS (ESI) m/z calcd for C19H16BrN4OS ([M + H]+), 427.0228; found, 
427.0211. HPLC purity = 99.8%.
3.2. 2-(5-((4-Bromobenzyl)thio)-4-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-
yl)pyridine—The material was prepared as previously described.1 HPLC purity = 100%.
3.3. 2-(5-((4-Bromobenzyl)thio)-4-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-
yl)pyridine—The 3-pyridine-containing thione (75 mg, 0.28 mmol) and 4-bromobenzyl 
bromide (84 mg, 0.33 mmol, 1.2 equiv) were reacted according to the general procedure to 
afford the product as a light yellow oil (73 mg, 0.17 mmol, 60% yield). Rf = 0.67 (10% 
MeOH in CH2Cl2). 1H NMR (CDCl3) δ 4.43 (s, 2H), 5.77 (s, 2H), 7.13 (dd, J = 4.8, 7.6 Hz, 
1H), 7.23 (td, J = 2.0, 8.8 Hz, 2H), 7.29–7.33 (m, 2H), 7.39 (td, J = 2.0, 8.4 Hz, 2H), 7.80 
(dt, J = 2.0, 8.0 Hz, 1H), 8.31 (td, J = 0.8, 8.4 Hz, 1H), 8.47 (dd, J = 0.8, 4.8 Hz, 1H), 8.52 
(d, J = 1.2 Hz, 1H), 8.55 (qd, J = 0.8, 4.8 Hz, 1H). 13C NMR (CDCl3, APT pulse sequence) 
δ d 123.4, 123.5, 124.4, 130.9, 131.9, 134.9, 137.2, 148.7, 149.2, 149.3; u 37.2, 46.5, 121.9, 
131.6, 135.8, 147.8, 152.7, 152.8. IR (neat) 1589, 1486, 1464, 1446, 1419 cm−1. HRMS 
(ESI) m/z calcd for C20H17BrN5S ([M + H]+), 438.0388; found, 438.0391. HPLC purity = 
99.8%.
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Structures of KOR agonists. Previous identification of triazole compounds with KOR 
agonist activity29,30 has led to the synthesis of compounds analyzed here.
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Triazole analogues stimulate G protein coupling, βarrestin2 recruitment, and ERK1/2 
phosphorylation to different degrees relative to U69,593. G protein coupling (A) identifies 
triazole analogues as potent, full agonists in the presence of [35S]GTPγS. High content 
imaging of βarrestin2 (B) illustrates that triazole analogues recruit βarrestin2 only at 
concentrations significantly higher than U69,593. ERK1/2 phosphorylation (C) measured by 
fluorescence intensity detection of the ratio of pERK1/2 to tERK1/2 concludes that triazole 
test compounds exceeds stimulation observed for U69,593. Assays were run with 
concentrations of indicated agonists and are displayed as percentage of maximal U69,593 
stimulation. Calculated potencies and efficacies are presented in Table 1. Data are presented 
as the mean ± SEM (n ≥ 3).
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Comparison of G protein signaling to βarrestin2 recruitment and ERK1/2 activation as a 
function of efficacy at each dose tested. Data are presented as the maximal stimulation at 
each agonist concentration normalized to U69,593. These equimolar plots present the 
comparison of each test agonist’s response profile to the stimulation produced by the 
reference agonist, U69,593. For comparison, each graph also presents an equimolar 
relationship of unity, slope equal to one. Each test agonist produces stimulation of G protein 
coupling before measurable βarr2 recruitment is observed. Conversely, the ERK 
phosphorylation produced by the test agonists is ligand dependent and some analogues 
approach both the reference agonist and the unity line.
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Bias factors (ΔΔLogR values) and relative activity ratios represented. (A) Relative activity of 
each test agonist (Emax/EC50) is presented relative to the reference agonist U69,593. (B) 
Bias factors were calculated using the operational model and are presented as the degree of 
bias toward G protein coupling and away from βarr2 recruitment and toward G protein 
coupling and away from ERK 1/2 phosphorylation relative to U69,593. The center of each 
figure presents a value equal to one (as defined by the reference agonist). The bias factor of 
the reference agonist is equal to one and the values greater than one indicate bias toward G 
protein coupling compared to βarr2 recruitment or ERK phosphorylation. Values can be 
found summarized in Table 2.
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Schematic summarizing the SAR trends revealed when comparing the ratio of Bias Factors 
for each assay. Ratios were generated by dividing the bias factors for G protein vs βarr2 by 
the bias factors for G vs ERK1/2 activation from Table 2. A trend can be seen wherein the 
thiophenyl substitution increases the bias between G protein and ERK activation 
(denominator) resulting in a decrease in the ratio. The pyridyl substitution decreases the bias 
for G protein vs ERK activation (denominator) producing an increase in the ratio.
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